A Randomized Multicenter Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

This study compares 2 combinations of drugs to prevent graft-versus-host disease (GVHD): Tacrolimus/methotrexate and Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best for future transplant patients. The purpose of its companion study is to understand if the bacteria and proteins in your gut and body fluids can help doctors predict transplant outcomes.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Acute Leukemia,Chronic Myelogenous Leukemia (CML),Myelodysplasia,Lymphoma
• Age: Between 18 Years - 99 Years
• Gender: All